Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14744693 | 0.93 | L3MBTL1 (0.38) | EDNRBALDH1A1TSHRPLA2G2A | |
| SCHEMBL16428927 | 0.90 | EDNRB (0.42) | EDNRBKDM4EALDH1A1TSHRFEN1 | |
| SCHEMBL14745657 | 0.89 | EDNRB (0.41) | EDNRBKDM4EALDH1A1TSHRHPGD | |
| SCHEMBL14744608 | 0.88 | EDNRB (0.42) | EDNRBKDM4EALDH1A1TSHRFEN1 | |
| SCHEMBL14744875 | 0.85 | NPC1 (0.39) | EDNRBKDM4EALDH1A1TSHRHPGD | |
| SCHEMBL14745624 | 0.81 | GABRG2 (0.40) | EDNRBALDH1A1 | |
| SCHEMBL14744705 | 0.81 | EDNRB (0.34) | EDNRBALDH1A1PLA2G2A | |
| SCHEMBL14745242 | 0.80 | EDNRB (0.44) | EDNRBKDM4EALDH1A1HPGDPLA2G2A | |
| SCHEMBL14744918 | 0.80 | AADAT (0.38) | EDNRBKDM4EALDH1A1TSHRFEN1 | |
| SCHEMBL14745779 | 0.79 | EDNRB (0.40) | EDNRBALDH1A1TSHRFEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409905-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2750504-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033258-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | EDNRB 3885/4885KDM4E 4305/4885ALDH1A1 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.